Side-by-side · Research reference

IpamorelinvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED21/57 cited

BPhase 3HUMAN-REVIEWED25/54 cited

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

Ipamorelin

Survodutide

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

—

Origin

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

—

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

Ipamorelin

Survodutide

Standard dose

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

Once weekly

Lower / starter dose

100 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

—

Reconstitution

Bacteriostatic water; typical 2 mL per 5 mg vial

—

Timing

Pre-sleep + fasted preferred; 30 min away from food

—

Half-life

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

Ipamorelin

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

Ipamorelin

Survodutide

Cortisol elevation

Negligible vs other GHRPsRaun 1998

—

Prolactin elevation

NegligibleRaun 1998

—

Hunger

Mild appetite increase via ghrelin-receptor crosstalk

—

Injection site reaction

Mild irritation possible

—

GH excess (overdose)

Joint pain, edema, insulin resistance

—

IGF-1 elevation

Dose-dependent; monitor with chronic high-dose use

—

Cancer risk

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

Ipamorelin

Survodutide

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

29–31G, 4–8 mm insulin syringe.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

06Stack Synergy

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006

Survodutide

— no documented stacks